


COVID-19 early treatment: real-time analysis of 718 studies

Share Tweet Global Adoption


[All studies](#) [Early treatment](#) [Mortality](#) [Early treatment mortality](#) [Recent studies](#)

Analysis of the efficacy of early treatments for COVID-19. *Treatments do not replace vaccines and other measures. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage.*



Medications approved for early treatment by >2 countries. 55 countries have officially approved early treatment. For details see [global early treatment adoption](#).


All studies combined (pooled effects, all stages) c19early.com 6/27/21



Random effects meta-analysis of all studies combined (pooled effects, all stages). Treatments with 3 or fewer studies are shown in grey. Pooled results across all stages and outcomes depend on the distribution of stages and outcomes tested - for example late stage treatment may be less effective and if the majority of studies are late stage this may obscure the efficacy of early treatment. Please see the specific stage and outcome analyses.

Early treatment studies (pooled effects)


c19early.com 6/27/21




Random effects meta-analysis of early treatment studies (pooled effects). Treatments with 3 or fewer studies are shown in grey. Pooled results across all outcomes are affected by the distribution of outcomes tested, please see detail pages for specific outcome analysis.


All mortality results (all stages)

c19early.com 6/27/21





Random effects meta-analysis of all mortality results (all stages). Treatments with 3 or fewer studies are shown in grey. Pooled results across all stages depend on the distribution of stages tested - for example late stage treatment may be less effective and if the majority of studies are late stage this may obscure the efficacy of early treatment. Please see the specific stage analyses.



Random effects meta-analysis of early treatment mortality results. Treatments with 3 or fewer studies are shown in grey.

Recent studies (see the individual treatment pages for all studies):

6/24	Late Details	<i>Sabico et al., Nutrients, doi:10.33...</i>	Effects of a 2-Week 5000 IU versus 10...
6/24	Meta Details	<i>Pal et al., Jo...</i> meta-analysis	Vitamin D supplementation and clinic...
6/24	Late Details	<i>Gerlovin et a...</i> death, ↑22.0% , ...	Pharmacoepidemiology, Machine Lea...

6/22	News Details	<i>Misiones Mi...</i> News report on ivermectin use in Misiones, Argentina, showing significantly...	news	Results from ivermectin use from the ...
6/21	Late Details	<i>Arch et al., m...</i> Prospective PSM analysis of remdesivir use in the UK showing statistically s...	death, ↓19.9%, ...	Evaluation of the effectiveness of rem...
6/21	In Sili... Details	<i>Yadav et al., Research Square, d...</i> <i>In Silico</i> study showing stronger inhibition of SAR-CoV-2 for HCQ+favipiravir...		Repurposing the Combination Drug of...
6/19	Early Details	<i>Ahmadi et al...</i> RCT 60 outpatients in Iran, 30 treated with nano-curcumin showing lower ho...	hosp., ↓85.7%, ...	Oral nano-curcumin formulation effica...
6/18	Revie... Details	<i>Lind et al., Jo...</i> CDC analysis of ivermectin prescriptions in the US suggesting that, while na...	review	Increase in Outpatient Ivermectin Disp...
6/18	Late Details	<i>Schwartz et ...</i> Small early terminated late treatment RCT not showing significant differenc...	ICU, ↑133.3%, ...	Assessing the efficacy and safety of h...
6/18	In Vitr... Details	<i>Purwati et al...</i> <i>In Vitro</i> study of combinations of drugs showing antiviral efficacy of HCQ al...	<i>in vitro</i>	An in vitro study of dual drug combina...
6/18	Early Details	<i>Fischer et al...</i> RCT 202 outpatients in the USA showing significantly faster viral clearance, ...	death, ↓76.5%, ...	Molnupiravir, an Oral Antiviral Treatme...
6/18	Early Details	<i>Krolewiecki ...</i> Proof of concept RCT with 30 ivermectin patients and 15 control patients, s...	ventilation, ↑15...	Antiviral effect of high-dose ivermectin...
6/17	Meta Details	<i>Bryant et al., ...</i> Systematic review, meta analysis, and trial sequential analysis of 24 RCTs fi...	death, ↓62.0%, ...	Ivermectin for Prevention and Treatm...
6/17	Levels Details	<i>Jude et al., J...</i> Retrospective 80,670 people in the UK with vitamin D levels measured withi...	hosp., ↓71.6%, ...	Vitamin D deficiency is associated wit...
6/16	Late Details	<i>Horby et al., ...</i> RCT 9,785 hospitalized patients in the UK showing lower mortality with casi...	death, ↓6.0%, p...	Casirivimab and imdevimab in patient...
6/15	Revie... Details	<i>Zaidi et al., T...</i> Extensive review of 20 mechanisms of action of ivermectin for SARS-CoV-2.	review	The mechanisms of action of Ivermec...
6/15	In Vitr... Details	<i>Panchariya e...</i> <i>In Silico</i> and <i>In Vitro</i> study showing that ionic zinc inhibits SARS-CoV-2 main...	<i>in vitro</i>	Zinc2+ ion inhibits SARS-CoV-2 main ...
6/15	Early Details	<i>Aref et al., In...</i> RCT 114 patients in Egypt, 57 treated with ivermectin mucoadhesive nanos...	recov. time, ↓6...	Clinical, Biochemical and Molecular Ev...

6/14	Levels	Campi et al., ...	death, ↓ 24.3% , ...	Vitamin D and COVID-19 severity and ...
	Details	Prospective study of 103 hospitalized patients in Italy, showing very high pre...		
6/9	Late	Saib et al., P...	int./death, ↑ 12% ...	Lack of efficacy of hydroxychloroquin...
	Details	203 hospitalized patients in France, not showing significant differences with...		
6/8	Late	Singh et al., ...	death, ↓ 47.5% , ...	Safety and efficacy of antiviral therapy...
	Details	Very small early terminated RCT in India, showing lower mortality but witho...		
6/7	Late	Al Sulaiman ...	death, ↓ 35.0% , ...	Evaluation of Zinc Sulfate as an Adjun...
	Details	Retrospective 266 ICU patients showing lower mortality with zinc treatment...		
6/7	PrEP	Dinesh et al.,...	cases, ↓ 60.1% ,...	Hydroxychloroquine for SARS CoV2 P...
	Details	Prophylaxis study with 2,727 Indian healthcare workers, showing lower risk ...		
6/7	Levels	Dror et al., m...	severe case, ↓ 8% ...	Pre-infection 25-hydroxyvitamin D3 lev...
	Details	Retrospective 253 hospitalized patients in Israel showing higher mortality a...		
6/6	Levels	Diaz-Curiel, J...	ICU, ↓ 73.2% , p=...	The relationship between 25(OH) vita...
	Details	Retrospective 1,549 patients in Spain showing that the frequency of vitamin...		
6/6	N/A	Hariyanto et ...	death, ↓ 69.0% , ...	Ivermectin and outcomes from Covid-...
	Details	Systematic review and meta analysis of 19 RCTs showing mortality RR 0.31...		

We aim to cover the most promising early treatments for COVID-19. We use pre-specified effect extraction criteria that prioritizes more serious outcomes, for details see [methods](#). For specific outcomes and different treatment stages see the individual pages. Not all treatments are covered here, effectiveness has been reported for many other treatments in studies. Of the 718 studies, 503 present results comparing with a control group, 444 are treatment studies, 59 analyze outcomes based on serum levels, and 46 are meta analyses.

Please send us corrections, updates, or comments. *Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.*

Feedback

Submit

 Share  Tweet @CovidAnalysis FAQ Public domain CC0 1.0  